N-(1H-benzoimidazol-2-yl)-3-chloro-benzamide | 24363-92-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(1H-benzoimidazol-2-yl)-3-chloro-benzamide
• 英文别名: N-(1H-benzimidazol-2-yl)-3-chlorobenzamide
• CAS: 24363-92-6
• 化学式: C₁₄H₁₀ClN₃O
• mdl: MFCD03387311
• 分子量: 271.706
• InChiKey: NNOLHIYETJFEDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(1H-benzoimidazol-2-yl)-3-chloro-benzamide 、 alkaline earth salt of/the/ methylsulfuric acid 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 生成 N-(1-Butyl-1H-benzoimidazol-2-yl)-3-chloro-benzamide
  参考文献：
  名称：

  Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4

  摘要：

  High-throughput screening of a small-molecule compound library resulted in the identification of a novel series of N-acyl 2-aminobenzimidazoles that are potent inhibitors of interleukin-1 receptor-associated kinase-4. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.020
• 作为产物：
  描述：

  邻苯二胺 在 吡啶 、 溴 作用下， 反应 10.0h， 生成 N-(1H-benzoimidazol-2-yl)-3-chloro-benzamide
  参考文献：
  名称：

  Sluka, Jaroslav; Danek, Jaroslav; Bedrnik, Petr, Collection of Czechoslovak Chemical Communications, 1981, vol. 46, # 11, p. 2703 - 2708

  摘要：

  DOI：

文献信息

• METHOD FOR PRODUCING NON-ISOCYANATE POLYURETHANES
  申请人：Henkel AG & Co. KGaA

  公开号：US20210324141A1

  公开（公告）日：2021-10-21

  The present application is directed to a method for producing non-isocyanate polyurethanes. More particularly, the application is directed to method for producing non-isocyanate polyurethanes by using a single catalyst component selected from an amidoindole derivative, a benzimidazole derivative and a squaramide derivative.

  本申请涉及一种生产非异氰酸酯聚氨酯的方法。更具体地说，该申请涉及一种通过使用从酰胺吲哚衍生物、苯并咪唑衍生物和方酰胺衍生物中选择的单一催化剂组分来生产非异氰酸酯聚氨酯的方法。
• TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
  申请人：Wynne Graham Michael

  公开号：US20090075938A1

  公开（公告）日：2009-03-19

  There are disclosed compound of Formula (1): A 1 , A 2 , A 3 and A 4 which may be the same or different, represent N or CR 1 , X is a divalent group selected from O, S(O) n , C═W, NR 4 , NC(═O)R 5 and CR 6 R 7 , W is O, S, NR 20 , Y is N or CR 8 , one of R 4 , R 5 , R 6 , R 8 , R 9 and NR 20 represents -L-R 3 , in which L is a single bond or a linker group, additionally, R 1 , R 3 -R 9 , which may be the same or different, independently represent hydrogen or a substituent and R 20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO 2 , NR 30 R 31 , in which R 30 and R 31 , which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R 30 and R 31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A 1 -A 4 each represent CR 1 , then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CR 6 R 7 , R 6 and R 7 , together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.

  公式（1）的化合物被揭示：A1，A2，A3和A4，它们可以相同或不同，代表N或CR1，X是从O，S（O）n，C═W，NR4，NC（═O）R5和CR6R7中选择的二价基团，W是O，S，NR20，Y是N或CR8，R4，R5，R6，R8，R9和NR20中的一个表示-L-R3，在其中L是单键或连接基团，此外，R1，R3-R9可以相同或不同，独立地表示氢或取代基，R20表示氢，羟基，可以用芳基取代的烷基，可以用芳基取代的烷氧基，芳基，CN，可以用芳基取代的烷氧基，可以用芳基取代的芳氧基，可以用取代基取代的烷酰基，可以用取代基取代的芳酰基，NO2，NR30R31，在其中R30和R31可以相同或不同，表示氢，可选地取代的烷基或可选地取代的芳基；此外，R30和R31中的一个可以表示可选地取代的烷酰基或可选地取代的芳酰基，n表示从0到2的整数，另外，当相邻的A1-A4中的一对表示CR1时，那么相邻的碳原子及其取代基可以形成环B，当X为CR6R7时，R6和R7与它们附着的碳原子一起可以形成环C，或其药学上可接受的盐，在制造用于治疗和/或预防杜氏肌萎缩症，贝克肌萎缩症或消瘦症的药物时使用。
• Drug Combinations for the Treatment of Duchenne Muscular Dystrophy
  申请人：Wynne Graham Michael

  公开号：US20110195932A1

  公开（公告）日：2011-08-11

  Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations.

  本发明涉及与一种或多种化合物（1）的一个或多个辅助剂组合的组合物，以制备这些组合物的过程，以及这些组合物的各种治疗用途。还提供了包含这些组合物的制药组合物，以及使用这些组合物治疗杜氏肌营养不良症、贝克肌营养不良症或消瘦的方法。
• DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
  申请人：Summit Corporation PLC

  公开号：US20140011782A1

  公开（公告）日：2014-01-09

  Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations.

  该专利涉及包含（或基本上由）一个或多个式（1）化合物和一个或多个辅助剂的组合物，以及制备这些组合物的方法，以及这些组合物的各种治疗用途。此外，还提供了包含这些组合物的药物组合物以及使用这些组合物治疗杜兴肌肉萎缩症，贝克肌肉萎缩症或消瘦症的方法。
• 13C NMR spectra and biological activity of N-(1H-benzimidazol-2-yl)benzamides
  作者：V. S. Pilyugin、Yu. E. Sapozhnikov、A. M. Davydov、G. E. Chikisheva、T. P. Vorob’eva、E. V. Klimakova、G. V. Kiseleva、S. L. Kuznetsova、R. D. Davletov、N. A. Sapozhnikova、R. Kh. Yumadilov

  DOI：10.1134/s1070363206100264

  日期：2006.10

  Derivatives of 1H-benzimidazol-2-amine and halo-, nitro-, methoxy-, and hydroxy-substituted benzoic acids were synthesized, and their fungicide activity against pure Fusarium culmorum and Helminthosporium sativum cultures and pathogenic microflora of wheat and barley seeds in laboratory and field tests was studied. Some compounds were found to exhibit a strong fungicide activity.